Antitumor effect of combined intraperitoneal administration of human recombinant interferon-beta and interferon-gamma against intraabdominal carcinomatosis in nude mice.

Hidenori Kondo*  Noriaki Tanaka†
Yoshio Naomoto‡  Kunzo Orita**

*Okayama University,
†Okayama University,
‡Okayama University,
**Okayama University,
Antitumor effect of combined intraperitoneal administration of human recombinant interferon-beta and interferon-gamma against intraabdominal carcinomatosis in nude mice.*

Hidenori Kondo, Noriaki Tanaka, Yoshio Naomoto, and Kunzo Orita

Abstract

The development of useful therapy for intraabdominal carcinomatosis originating from gastrointestinal cancer is an important theme in cancer therapy. We developed recently an experimental model of intraabdominal carcinomatosis in nude mice by intraperitoneal transplantation of human colon cancer cells (RPMI 4788). Using this model, we investigated the antitumor effects of recombinant human interferon (rIFN)-beta and rIFN-gamma administered singly or in combination. Treatment was initiated 2 days after CD-1 nude mice were inoculated intraperitoneally with 5 X 10(6) RPMI 4788 cells. Intraperitoneal administration for 10 consecutive days of either rIFN-beta (2.5 X 10(5) IU/mouse/day) or rIFN-gamma (2.5 X 10(5) JRU/mouse/day) resulted in a significant prolongation of survival compared with the saline control group [survival in the control: 41.8 +/- 5.6 days (mean +/- SD)]. Combined administration of rIFN-beta and rIFN-gamma for 10 days yielded a marked synergistic effect on the prolongation of survival (114.0 +/- 8.2 days). However, combined administration of rIFN-beta and rIFN-gamma in a single dose equal to the total dose given fractionally over 10 days did not yield a synergistic effect. These results suggest that daily administration of rIFN-beta and rIFN-gamma combined may provide a highly potent antitumor effect against human peritoneal carcinomatosis.

KEYWORDS: antitumor effect, human recombinant interferon, synergistic effect, intrabdominal carcinomatosis, nude mice

*PMID: 3133927 [PubMed - indexed for MEDLINE]
Copyright (C) OKAYAMA UNIVERSITY MEDICAL SCHOOL
Antitumor Effect of Combined Intraperitoneal Administration of Human Recombinant Interferon-β and Interferon-γ against Intraabdominal Carcinomatosis in Nude Mice

Hidenori Kondo*, Noriaki Tanaka, Yoshio Naomoto and Kunzo Orita

First Department of Surgery, Okayama University Medical School, Okayama 700, Japan

The development of useful therapy for intraabdominal carcinomatosis originating from gastrointestinal cancer is an important theme in cancer therapy. We developed recently an experimental model of intraabdominal carcinomatosis in nude mice by intraperitoneal transplantation of human colon cancer cells (RPMI 4788). Using this model, we investigated the antitumor effects of recombinant human interferon (rIFN)-β and rIFN-γ administered singly or in combination. Treatment was initiated 2 days after CD-1 nude mice were inoculated intraperitoneally with $5 \times 10^6$ RPMI 4788 cells. Intraperitoneal administration for 10 consecutive days of either rIFN-β ($2.5 \times 10^6$ IU/mouse/day) or rIFN-γ ($2.5 \times 10^6$ JRU/mouse/day) resulted in a significant prolongation of survival compared with the saline control group [survival in the control: 41.8±5.6 days (mean±SD)]. Combined administration of rIFN-β and rIFN-γ for 10 days yielded a marked synergistic effect on the prolongation of survival (114.0±8.2 days). However, combined administration of rIFN-β and rIFN-γ in a single dose equal to the total dose given fractionally over 10 days did not yield a synergistic effect. These results suggest that daily administration of rIFN-β and rIFN-γ combined may provide a highly potent antitumor effect against human peritoneal carcinomatosis.

**Key words**: antitumor effect, human recombinant interferon, synergistic effect, intraabdominal carcinomatosis, nude mice

Interferons (IFNs) are classified into three major classes based on their antigenic and physicochemical properties: the leukocyte-derived IFN-α, fibroblast-derived IFN-β, and T-lymphocyte-produced IFN-γ. IFNs have antiviral, antitumor, and immunomodulating activities (1, 2). The cloning of IFN genes has led to a number of forms of recombinant human IFN (rIFN)-α as well as rIFN-β and rIFN-γ (3-5). rIFNs are now available in preparations of greater than 95% purity and can be produced in quantities large enough for clinical trials. rIFNs were expected to have antitumor effects, but efficacy has been limited to only certain malignant tumors when the rIFNs were administered systemically (6). Hence, local administration of IFNs has been gaining...
attention as a new approach to IFN therapy (6). Furthermore, many authors have reported the synergistic effect of combined IFN therapy, particularly the combinations of IFN-α and IFN-γ, or IFN-β and IFN-γ (7-15).

At the present time, the prognosis of peritoneal carcinomatosis from gastrointestinal cancer is poor, and a definitive therapy has not yet been developed. In addition, peritoneal recurrence is the most common form of post-operative recurrence of gastrointestinal cancer (16). Therefore, the development of a prophylaxis and treatment for peritoneal carcinomatosis is greatly awaited.

Recently, we developed an experimental model of intraabdominal carcinomatosis using human colon cancer cells in nude mice (17). In the present study, we examined the antitumor effect of intraperitoneal administration of rIFN-β and rIFN-γ in combination using this in vivo nude mouse model in order to study new strategies of IFN therapy.

Materials and Methods

Tumor cells. RPMI 4788 cells derived from a human colon cancer were kindly supplied by Roswell Park Memorial Institute (Buffalo, N.Y.). The tumor cells were maintained in RPMI 1640 medium (Nissui Pharmacological Co., Tokyo, Japan) supplemented with 10% fetal calf serum (Gibco Laboratories, Grand Island, N.Y.) at 37°C in a humidified 5% CO₂ atmosphere. The characteristics of this tumor cell line have been described in detail previously (18). Cells in the exponentially proliferating phase were harvested for the experiments. Histological examination showed that the tumors transplanted subcutaneously into nude mice were poorly differentiated adenocarcinomas.

Animals. Six- to 7-week-old CD-1 (ICR) nu/nu male nude mice were obtained from Charles River Japan, Inc., Kawasaki, Japan. Throughout the experiment, the mice were maintained under specific pathogen-free conditions using laminar flow racks and were fed sterile food and water in our experimental animal center.

Interferons. Recombinant human interferon-β (rIFN-β) produced by Escherichia coli (Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan) had a purity of over 99.5% and a specific activity of over 5×10⁷ international units (IU)/mg protein (19). Recombinant human interferon-γ (rIFN-γ) produced by E. coli (Kyowa Hakko Kogyo Co., Ltd, Tokyo, Japan) had a purity of over 99% and a specific activity of over 5×10⁴ Japanese reference units (JRU)/mg protein (20). The titer of rIFN-β was expressed as IU/ml of reference IFN-β (J-Ref-02; National Institute of Health, Tokyo), which had been established based on the IU of WHO IFN-β reference (G 023-902-527). The titer of rIFN-γ was expressed as JRU/ml of Japanese rIFN-γ reference (J-Rr-40101; National Institute of Health), which had been established based on the IU of WHO IFN-γ reference (Gg 23-901-530). rIFNs were dissolved in physiological saline for the experiments.

Establishment of intraabdominal carcinomatosis with ascites in nude mice. The details of this nude mouse model have been described previously (17). Briefly, RPMI 4788 cells were harvested with a solution of 0.25% trypsin in PBS and suspended in PBS. CD-1 nude mice were inoculated intraperitoneally with 5×10⁴ viable RPMI 4788 cells/mouse in 0.5 ml of PBS using a 27-gauge needle (day 0). Peritoneal dissemination of tumor cells progressed in the abdominal cavity of the nude mice after the inoculation. All nude mice had ascites accumulation, and died of cachexia and remarkable retention of ascites in a relatively short time. In the abdominal cavity, bloody ascites and peritoneal dissemination of tumor on the greater omentum, mesocolon and diaphragma were common findings. Histological examination of the peritoneal tumors showed poorly differentiated adenocarcinomas.

Experimental schedule. Experiment 1. From day 2 through day 11, mice were given daily intraperitoneal injections (0.2 ml/mouse) of rIFN-β (2.5×10⁴ IU/mouse/day) and rIFN-γ (2.5×10⁵ JRU/mouse/day), singly or in combination. Saline (0.2 ml/mouse) in place of rIFNs was injected from day 2 for 10 consecutive days into mice of one control group (negative control group). Mitomycin C (MMC, Kyowa Hakko
Kondo et al.: Antitumor effect of combined intraperitoneal administration

Antitumor Effect of Combined rIFN-β and rIFN-γ

or in combination. Because rIFN-β and rIFN-γ exhibited direct antiproliferative activity against RPMI 4788 cells in vitro in a dose-dependent manner (21), we designed studies to determine whether they were also active in vivo against the same tumor cells.

As shown in Fig. 1-(A) and Table 1, rIFN-β and rIFN-γ significantly prolonged the survival time when administered individually (Experiment 1). The mean survival time was 87.0 ± 33.8 days (mean ± SD, p < 0.01 vs control) in the rIFN-β group and 72.2 ± 23.6 days (p < 0.05 vs control) in the rIFN-γ group, while it was 41.8 ± 5.6 days in the saline control group. The survival time in the MMC group (positive control) was 95.6 ± 33.9 days (p < 0.01). In the combined treatment group, the survival time was 114.0 ± 8.2 days (p < 0.01 vs control).

As shown in Fig. 1-(B) and Table 1, daily administration of rIFN-β and rIFN-γ individually at a dose one-fifth of that in Experiment 1 did not result in significantly prolonged survival (rIFN-β, 62.4 ± 9.8 days; rIFN-γ, 58.6 ± 12.2 days) compared

Results

Antitumor effect of daily intraperitoneal administration of rIFN-β and rIFN-γ singly

Table 1 Antitumor effect of rIFN-β and rIFN-γ, singly or in combination, against experimental intrabdominal carcinomatosis in nude mice

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Mean ± SD</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Experiment 1 a</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control (saline)</td>
<td>41.8 ± 5.6</td>
<td>36 – 49</td>
</tr>
<tr>
<td>rIFN-β</td>
<td>87.0 ± 33.8</td>
<td>50 – &gt;120</td>
</tr>
<tr>
<td>rIFN-γ</td>
<td>72.2 ± 23.6</td>
<td>46 – 109</td>
</tr>
<tr>
<td>rIFN-β + rIFN-γ</td>
<td>114.0 ± 8.2</td>
<td>104 – &gt;120</td>
</tr>
<tr>
<td>MMC</td>
<td>95.6 ± 33.9</td>
<td>51 – &gt;120</td>
</tr>
<tr>
<td><strong>Experiment 2 b</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control (saline)</td>
<td>47.8 ± 11.9</td>
<td>36 – 66</td>
</tr>
<tr>
<td>rIFN-β</td>
<td>62.4 ± 9.8</td>
<td>49 – 75</td>
</tr>
<tr>
<td>rIFN-γ</td>
<td>58.6 ± 12.8</td>
<td>45 – 71</td>
</tr>
<tr>
<td>rIFN-β + rIFN-γ</td>
<td>71.1 ± 14.5</td>
<td>54 – 88</td>
</tr>
</tbody>
</table>

a: The doses of recombinant human interferons, rIFN-β and rIFN-γ, used in this experiment was 2.5 x 10^4 IU or JRU/mouse/day. Details of the experimental conditions are described under Materials and Methods.

b: The daily dose of rIFNs administered was one-fifth of that in Experiment 1. Details of the experimental conditions are described in Materials and Methods.

c: Statistical significance of differences (Mann-Whitney U test) d vs e, g, h: p < 0.01; d vs f: p < 0.05; f vs g: p < 0.05; i vs j, k: not significant; i vs l: p < 0.05; j, k vs l: not significant.
Fig. 1  Survival curves of nude mice with experimental intraabdominal carcinomatosis following intraperitoneal administration of rIFN-β and rIFN-γ, singly or in combination. Mice were inoculated intraperitoneally (i.p.) with 5 × 10⁶ RPMI 4788 cells/mouse (day 0). Each group included 5 mice. Treatment was initiated from day 2.

(A) Experiment 1: rIFN-β (2.5 × 10⁴ IU/mouse/day) and rIFN-γ (2.5 × 10⁴ JRU/mouse/day) were administered i.p., singly or in combination, for 10 consecutive days from day 2. Control (saline) (●), rIFN-β (◇), rIFN-γ (□), rIFN-β + rIFN-γ (◇). MMC (2 mg/kg/day) (◇) was injected i.p. on day 2.

(B) Experiment 2: rIFN-β (5.0 × 10⁴ IU/mouse/day) and rIFN-γ (5.0 × 10⁴ JRU/mouse/day) were administered i.p., singly or in combination, for 10 consecutive days from day 2. Control (saline) (●), rIFN-β (◇), rIFN-γ (□), rIFN-β + rIFN-γ (◇).

(C) Experiment 3: rIFN-β (2.5 × 10⁴ IU/mouse/day) and rIFN-γ (2.5 × 10⁴ JRU/mouse/day) were administered i.p., singly or in combination, on day 2. Control (saline) (●), rIFN-β (◇), rIFN-γ (□), rIFN-β + rIFN-γ (◇).
with the control group (47.8 ± 11.9 days) (Experiment 2). However, daily combined administration of rIFN-β and rIFN-γ yielded a significant antitumor effect (71.0 ± 14.5 days, p < 0.05) compared with the control group.

Antitumor effect of one intraabdominal administration of rIFN-β and rIFN-γ singly or in combination (Experiment 3). The antitumor effect of a single dose of rIFN-β and rIFN-γ, which equaled the total dose used in Experiment 1, was examined. As shown in Fig. 1-(C) and Table 2, a single administration of rIFN-β alone resulted in significantly prolonged survival (mean survival time: 79.0 ± 16.0 days, p < 0.01 vs control), while rIFN-γ alone (58.2 ± 13.1 days) did not yield a significant antitumor effect compared with the control group (49.2 ± 8.2 days). A single administration of rIFN-β and rIFN-γ in combination (67.4 ± 11.5 days, p < 0.05 vs control) at the same total dose used in Experiment 1, did not afford a synergistic effect.

Table 2 Antitumor effect of a single administration of rIFN-β and rIFN-γ, individually or in combination, against experimental intraabdominal carcinomatosis in nude mice

<table>
<thead>
<tr>
<th>Treatment*</th>
<th>Mean survival time (days)</th>
<th>Mean ± SD</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (saline)</td>
<td>49.2 ± 8.2c</td>
<td>41–62</td>
<td></td>
</tr>
<tr>
<td>rIFN-β</td>
<td>79.0 ±16.0d</td>
<td>64–100</td>
<td></td>
</tr>
<tr>
<td>rIFN-γ</td>
<td>58.2 ±13.1e</td>
<td>39–73</td>
<td></td>
</tr>
<tr>
<td>rIFN-β+rIFN-γ</td>
<td>67.4 ±11.5f</td>
<td>57–85</td>
<td></td>
</tr>
</tbody>
</table>

a: Experimental conditions are described under Materials and Methods (Experiment 3).

b: Statistical significance of differences (Mann-Whitney U test) e vs d: p < 0.01; c vs e: not significant; c vs f: p < 0.05; d, e vs f: not significant.

Discussion

Intraperitoneal administration of IFNs is a form of intraseosal administration which is hoped to give a good antitumor effect against malignant ascites. In this study, we demonstrated that: 1) rIFN-β and rIFN-γ had dose-dependent antitumor activities in vivo. 2) Daily administration of either rIFN-β or rIFN-γ was more effective than a single administration of either rIFN at the same total dose. 3) Daily administration of rIFN-β and rIFN-γ in combination yielded synergistic (Experiment 1) or additive (Experiment 2) antitumor activity, while a single administration of the rIFNs in combination did not yield a synergistic effect. Kitahara et al. (22) reported that therapy with a single, large dose of IFNs was not effective against nude mouse-transplantable human tumors (ascites form), while long-term, multiple dose therapy (same total dose) was very effective. In our experiments, daily administration of either rIFN-β or rIFN-γ, provided a more potent antitumor effect than a single administration of either rIFN, although a single administration of rIFN-β provided a significant antitumor effect compared with the control. This difference is considered to be due to differences in the number of inoculated tumor cells and the sensitivity of the tumor cells in vivo to rIFN-β.

A synergistic increase in the antitumor effect of IFNs when administered in combination, particularly IFN-γ with IFN-α or IFN-β, has been reported by several authors. Fleischmann et al. (7, 8) showed that partially purified murine IFN-γ potentiated the antitumor effects of murine IFN-β both in vivo and in vitro. In the in vivo studies, IFN-γ (25 U/day), which alone had no effect on the growth of P388 lymphocytic leukemia tumors, significantly enhanced the growth-inhibitory capacity of IFN-β (7). Similar synergism between murine IFN-γ and murine IFN-α or IFN-β was reported in in vitro antiproliferative assays (8). De Clercq et al. (9) reported synergism in the antitumor effects of partially purified murine...
IFN-β and IFN-γ against L1210 leukemia cells. These earlier studies, however, were performed with partially purified IFN preparations known to be contaminated with lymphokines which could potentiate the IFN activities. The synergism between IFNs has been confirmed with pure recombinant IFNs. Czarniecki et al. (11) and Denz et al. (12) reported that combining rIFN-γ with rIFN-α or rIFN-β resulted in synergistic potentiation of activity in vitro. Recently, Nosoh et al. (15) reported synergism between rIFN-α and rIFN-γ against human tumor xenografts transplanted subcutaneously in nude mice. To our knowledge, the present study is the first to demonstrate efficacy of intraperitoneal administration of rIFN-β and rIFN-γ in combination against intraabdominal carcinomatosis in nude mice. In this study, IFN-β was selected because pharmacokinetic experiments indicated that, compared with IFN-α, it tends to remain in tissues where it is inoculated (23).

In the experimental model of intraabdominal carcinomatosis developed by the authors, intraperitoneal inoculation of a set number of tumor cells causes death by tumor in mice in a relatively short time, thereby allowing evaluation of antitumor efficacy of the drug from prolongation of mouse survival time. Moreover, as tumor cells derived from humans are used, it is an ideal model for studying the direct antitumor effect of human IFNs, which have high species-specificity, and for obtaining results which closely approximate actual clinical results.

Two mechanisms are thought to participate in the antitumor activity of IFN. One of these is direct antiproliferative activity against tumor cells, while the other is activation of NK cells or macrophages which act on the immune system, hence leading to lysis of the tumor cells. In the present in vivo assay system, the IFNs were considered to have direct antitumor activity and not to have indirect activity via mouse immune systems. However, when used in a human system, action of IFNs via the host defense mechanism must be considered in addition to direct antitumor activity, as indicated by Berk et al. (24) and Rambaldi et al. (25), who found that intraperitoneal administration of IFN-α and IFN-β activates NK cells in malignant ascites. Saito et al. (26) characterized the antiproliferative supernatant from ascites-associated rIFN-γ-treated macrophages and indicated the possibility that a component of the supernatant responsible for antiproliferative activity has antigenic determinants similar to those of tumor necrosis factor (TNF).

In conclusion, our results suggest that daily, combined administration of rIFN-β and rIFN-γ may provide highly potent antitumor activity against peritoneal carcinomatosis originating from human gastrointestinal cancer. In clinical practice, this method of administration could be applied not only as therapy for terminal peritoneal carcinomatosis, but also as postoperative adjuvant therapy for cases of gastrointestinal cancer positive for Douglas cul-de-sac cells. In addition, IFN has few side effects and can thus be used repeatedly over long periods compared with conventional anticancer agents.

Acknowledgment. The authors are grateful to Kyowa Hakko Co. Ltd. for the supply of purified rIFN-β and rIFN-γ.

References


Received September 3, 1987; accepted February 2, 1988